Global CRISPR Market Insights, Opportunity Analysis, Market Shares and Forecast 2017 - 2023

  • ID: 3569608
  • Report
  • Region: Global
  • 140 pages
  • Occams Business Research and Consulting
1 of 4

FEATURED COMPANIES

  • Caribou Biosciences
  • CRISPR therapeutics
  • GenScript
  • Intellia
  • New England Biolabs
  • Precision biosciences
  • MORE
Clustered regularly-interspaced short palindromic repeats also known as CRISPR is a gene editing tool. CRIPSR commercialization began in 2012 with emergence of number of startups and venture capitalists and showing their interest in infusing money into this technology. Academic and research firms are the main consumers of CRISPR gene editing tool followed by biotechnology companies. The number of patents for CRISPR is outclassing the patents of other gene editing tools such as ZFN and TALEN. The market is driven by high demand for plasmids, synthetic genes and high quality gene slicing techniques. Growing drug discovery, biotechnology and proteomics markets are also driving the market growth.

The market is This is driven by the fact that CRISPR is a new technology which is simple, more efficient and cost effective as compared to its peers. High adoption both in biotech and pharma industry along with high level of research is also responsible for high growth rate.

The market for CRISPR technology is niche. The number of companies are still very less and most of the companies are start-ups which are going through rounds of funding. Some of the major companies include Editas, Intellia, Sigma Eldrich, Oregene, Gene Script, Thermo Fisher Scientific and others. Most of the companies are working on developing CRISPR products along with the approval and commercialization of such products. These companies have successfully attracted major investments from big VC firms and companies such as Google and DuPont. These companies are relying on the disruptive nature of the technology. CRISPR has the capability to open new markets for gene surgery and genetically modified organisms. However, there are major concerns from the scientific community regarding the misuse of such technology in human cloning. Geographically North America leads the market race followed by Europe and Asia Pacific.

Companies profiled include
1. Thermo Fisher Scientific
2. Editas Medicine
3. Caribou Biosciences
4. CRISPR therapeutics
5. Intellia
6. Cellectis
7. Horizon discovery PLC
8. Sigma Aldrich
9. Precision biosciences
10. GenScript
11. Sangamo Biosciences Inc.
12. Lonza group limited
13. Integrated DNA technologies
14. New England Biolabs
15. Oregene Technologies
16. Transposgen Biopharmaceuticals

This Research report covers
1. Historical data
2. Revenue forecasts, growth rates and CAGR up to 2021
3. Industry Analysis
4. Competitive Analysis
5. Key geographic growth data

Note:
Please allow up to 72 hours for delivery.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Caribou Biosciences
  • CRISPR therapeutics
  • GenScript
  • Intellia
  • New England Biolabs
  • Precision biosciences
  • MORE
1. Executive Summary
1.1. Estimation Methodology

2. Market Overview
2.1. CRISPR- Introduction
2.2. Value chain analysis
2.3. Key buying criteria
2.4. Research and development
2.4.1. Patent analysis
2.5. CRISPR vs. Conventional gene editing tools
2.5.1. TALEN
2.5.2. ZFN
2.6. CRISPR: Novel initiatives
2.6.1. CRISPR/Cas9 technology
2.6.2. CRISPR as a gene editing tool to treat genetic disorders.
2.6.3. CRISP as a gene editing tool in drug development.
2.7. Strategic Recommendation and conclusion

3. Sector Analysis
3.1. Gene Editing Market

4. Market Determinants
4.1. Drivers
4.1.1. Rise in drug discovery market
4.1.2. Demand for synthetic genes
4.1.3. High prevalence of genetic birth disorders
4.1.4. Age related genetic disorders
4.1.5. Rise in the healthcare research and development budgets
4.1.6. Venture capital
4.2. Restraints
4.2.1. Ethical issues related to misuse of CRISPR gene editing tool
4.2.2 Limited awareness
4.2.3. Limited presence in Emerging markets
4.3. Opportunities
4.3.1 CRISPR gene editing can open the market for gene surgery.
4.3.2. Emerging contract research market in Asia
4.4. Challenges
4.4.1. Patent infringement
4.4.2. Presence of alternative gene editing tools

5. Market Segmentation
5.1. By Application
5.1.1. Genome Editing
5.1.2. Genetic engineering
5.1.3. gRNA Database/Gene Library
5.1.4. CRISPR Plasmid
5.1.5. Human Stem Cells
5.1.6. Genetically modified organisms/crops
5.1.7. Cell line engineering
5.2. By End user
5.2.1. Biotechnology companies
5.2.2. Pharmaceutical companies
5.2.3. Academic Institutes
5.2.4. Research and development institutes
5.3. Competitive Intelligence
5.3.1. Merger and Acquisitions
5.3.2. Innovation
5.3.3. Venture capital funding

6. Geographical Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. United Kingdom
6.2.2. France
6.2.3. Germany
6.2.4. Spain
6.2.5. Italy
6.3. Asia Pacific
6.3.1. China
6.3.2. Japan
6.3.3. India
6.4. Rest of the world

7. Company Profiling
1. Thermo Fisher Scientific
2. Editas Medicine
3. Caribou Biosciences
4. CRISPR therapeutics
5. Intellia
6. Cellectis
7. Horizon discovery PLC
8. Sigma Aldrich
9. Precision biosciences
10. GenScript
11. Sangamo Biosciences Inc.
12. Lonza group limited
13. Integrated DNA technologies
14. New England Biolabs
15. Oregene Technologies
16. Transposgen Biopharmaceuticals
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Thermo Fisher Scientific
Editas Medicine
Caribou Biosciences
CRISPR therapeutics
Intellia
Cellectis
Horizon discovery PLC
Sigma Aldrich
Precision biosciences
GenScript
Sangamo Biosciences Inc.
Lonza group limited
Integrated DNA technologies
New England Biolabs
Oregene Technologies
Transposgen Biopharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll